Nvwm LLC Acquires 2,697 Shares of Cencora, Inc. $COR

Nvwm LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 44,950.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 2,703 shares of the company’s stock after purchasing an additional 2,697 shares during the quarter. Nvwm LLC’s holdings in Cencora were worth $812,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Cencora during the second quarter valued at $5,154,136,000. T. Rowe Price Investment Management Inc. grew its position in Cencora by 160.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after buying an additional 4,123,795 shares in the last quarter. Bank of America Corp DE grew its position in Cencora by 6.9% in the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock valued at $1,300,033,000 after buying an additional 267,318 shares in the last quarter. Amundi increased its stake in Cencora by 43.5% during the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock valued at $630,855,000 after buying an additional 676,066 shares during the period. Finally, Carmignac Gestion increased its stake in Cencora by 58.7% during the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after buying an additional 646,112 shares during the period. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares of the company’s stock, valued at $6,305,754.60. The trade was a 36.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.38% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of a number of recent analyst reports. Royal Bank Of Canada restated a “sector perform” rating and set a $330.00 price target on shares of Cencora in a research report on Tuesday, September 8th. Bank of America increased their price objective on shares of Cencora from $285.00 to $310.00 in a report on Tuesday, July 21st. Morgan Stanley increased their price objective on shares of Cencora from $342.00 to $346.00 and gave the company an “overweight” rating in a report on Friday, August 7th. UBS Group raised their price objective on shares of Cencora from $412.00 to $430.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Evercore reissued an “outperform” rating and set a $350.00 target price (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.69.

Cencora Trading Up 1.7%

Shares of COR stock opened at $335.85 on Thursday. The stock has a 50-day simple moving average of $319.66 and a 200 day simple moving average of $302.88. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The stock has a market capitalization of $64.09 billion, a P/E ratio of 24.95, a P/E/G ratio of 1.69 and a beta of 0.58. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The firm had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. During the same period in the previous year, the company earned $4.00 earnings per share. Cencora’s revenue was up 5.1% compared to the same quarter last year. On average, sell-side analysts expect that Cencora, Inc. will post 17.87 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were given a dividend of $0.60 per share. The ex-dividend date was Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 17.83%.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.